Downloading...
Download

ARDX

ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X: Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week, I would consider purchasing the 4usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.45. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NASDAQ:ARDXLong
by TopgOptions
730% upside stock according to CitigroupArdelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NASDAQ:ARDXLong
by TopgOptions
7
ARDX 500mil Revenue Forecasts for a Penny Stock | The 10X call??Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NASDAQ:ARDXLong
by TopgOptions
1
ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. Tagged as SHORT because I expect more short-term losses before reversal (BULLS). 🔸 Summary and potential trade setup ::: ARDX daily/candle chart chart overview ::: strong bullish chart accumulation ::: buying near range lows makes sense now ::: 100% gains BUY/HOLD setup ::: best reload BULLS is 3.80-4.40 USD ::: TP1 Bulls is 50% gains ::: TP2 Bulls is 100%+ gains ::: targets based on measured move ::: just buy/hold it and get paid ::: 100%+ gains on BUY SIDE medium-term ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9/Combo update: N/A ::: Sentiment mid-term: BULLS/reversal/accumulation ::: Sentiment outlook short-term: BEARS
NASDAQ:ARDXShort
by ProjectSyndicate
4
ARDX - Perfect Retracement - Bullish Momentum Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipation. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA. P/E Current -1.32 P/E Ratio (with extraordinary items) -1.30 SHORT INTEREST 414.63K 07/31/19 Average Recommendation: BUY Average Target Price: 10.75
NASDAQ:ARDXLong
by DEXWireNews
1